Trades on 1 secondary market
Oblenio Bio
Oblenio Bio is a clinical-stage biotechnology company developing tri-specific antibody immunotherapies for refractory autoimmune diseases. Its lead candidate, LBL-051, is a tri-specific T-cell engager targeting BCMA, CD19, and CD3 to deplete B-cells and pursue long-term, drug-free remission and immu
Oblenio Bio is an API provider whose private shares are listed on 1 secondary market: EquityZen.
Where It Trades
Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.